3-year overall survival rates improved with FLOT chemotherapy in resectable esophageal cancer patients compared to neoadjuvant chemoradiation.

Phase 3 ESOPEC trial revealed that perioperative chemotherapy with FLOT protocol improved overall survival in resectable esophageal cancer patients vs neoadjuvant chemoradiation. FLOT patients had a median OS of 66 months vs 37 months for CROSS group. 3-year OS rates were 57% vs 51%, suggesting FLOT chemotherapy before/after surgery for better tumor cure.